|
Le immunoglobuline endovena (IGEV) sono ottenute dal plasma proveniente da un elevato numero di donazioni. La maggioranza delle preparazioni commerciali contiene in misura predominante (>90%) Ig policlonali con una normale presenza delle sottoclassi ed una piccola aliquota di IgA e IgM. Le indicazioni alla terapia con IgEV sono raccolte nella tabella che segue.
Effetti collaterali Per il loro trattamento è sufficiente interrompere l’infusione oppure attuare una premedicazione con steroidi. Rari ma gravi eventi avversi sono:
Bibliografia
1. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas I. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998 Feb; 50 (2): 398-402. 2. Alcock GS, Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. The Cochrane database Syst Rev 2002(3): CD003313 3. Alejandria, MM; Lansang, MA; Dans LF; Mantaring JBV. Intravenous Immunoglobulins for treating sepsis and septic shock. (Review). The Cochrane database Syst Rev 2002(1):CD001090 4. Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1993;43:876-879 5. Azulay JP, Blin O, Pouget J, Boucraut J,Bille-turc f, Carles G, Serratrice G. Intravenous immunoglobulin treatment in patient with motor neuron syndromes associated with anti-GM1 antibodies; a double-bind, placebo-controlled study. Neurology 1994 Mar; 44 (3Pt1):429-32. 6. Bird SJ. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology. 1992, 42: 1442-3 7. Blanchette VS; Imbach P; Andrew M et al. - Randomized trial of intravenous immunoglobulin G, intravenous anti-D and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994: 344: 703-707. 8. Boughton BJ, Jackson N, Lim S, Smith N.- Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukemia and secondary hypogammaglobulinaemia. Clin. Lab. Haem. 1995: 17: 75 - 80. 9. Briellmann RS, Nydegger UE, Sturzenegger M, Fierz L, Hess CW, Hauser SP. Long term treatment of chronic inflammatory demyelinating polyradiculoneuropathy: combinations of corticosteroids, plasma exchange and intravenous immunoglobulin. Eur Neurol 1998;39:190-191. 10. Bussel J; Kaplan C; Mc Farland J; - Recomendations for the evaluation and treatment of neonatal autoimmune and alloimmune thrombocytopenia. The Working Party on Neonatal Immune Thrombocytopenia of the Neonatal Hemostasis Subcomittee of Scientific and Standardization Committee of the ISHT. Thromb Haemost. 1991: 65:631 - 634. 11. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG, for The UK Group For Immunoglobulin Replacement Therapy In Multiple Myeloma. - Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateau- phase multiple myeloma. Lancet 1994: 343: 1059 -1063. 12. Cherin P, Pelletier S, Teixera A, Laforet P et al. Results and long-term follow-up of intravenous immunoglobulin infusion in chronic, refractory polymyoisitis: an open study with 35 adult patients. Arthritis Rheumatol 2002; 46(2):467-74 13. Couchoud, C. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation. [Systematic Review] Cochrane Renal Group Cochrane Database Syst Rev 2000(3): 14. Christiansen OB. Intravenous immunoglobulin in the prevention of recurrent spontaneous abortion. The European experience. Am J Reprod Immunol 1998; 39: 77- 81 15. Dagoglu T, Ovali F, Smanci N, Bengisu E. High dose intravenous immunoglobulin therapy for rhesus haemolytic disease. - J. Int .Med Res 1995: 23 : 264 -271. 16. Dalakas MC: The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscolar diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004;102(3):177-93 17. Dalakas MC, Quarles RH, Farrer RG et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996; 40: 792-95 18. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion body, myositis with IVIg: a double-blind, placebo-control study. Neurology 1997;48:712-716 19. Daya S, Gunby J, Clark DA. Intravenous immunoglobulin therapy for recurrent spontaneous abortion: a meta-analysis. Am J Reprod Immunol 1998; 39: 69-76 20. Dunkel IJ; Bussel JB; - New developements in the treatment of neutropenia. - Am J. Dis Child 1993: 147: 994- 1000. 21. Durongpisitkul K, Gurunaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin tretment. Pediatrics 1995; 96: 1057-1061 22. Duse M, Notangelo LD, Tiberi S, Menegati E, Plebani A, Ugazio AG. Intravenous immune globulin in the treatment of intractable childhood epilepsy. Clinical and Experimental Immunology 1996 May; 104 Suppl 1: 71-6 23. Engineer L, Ahmed R. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data. J Am Acad Dermatol 2001; 44(1):83-88 24. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing- remitting multiple sclerosis. Lancet 1997 Mar 1; 349 (9052): 589-93 25. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and hight-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997 jun; 41 (6) 789-96 26. Gelfand EW. Use of IgEV in the treatment of immune mediate dermatologic disorders. J Investig Dermatol Symp Proc 2004; 9(1):92-96 27. Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic CMV disease in transplant recipients - A meta-analysis. Clin Transplantation 1994;8(1):10-18. 28. Godeau B, Chevret s, Varet B, Lefrere F, Zini JM et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomized, multicentre trial. Lancet 2002; 359 (9300):23-9 29. Goodric JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD- Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogenic marrow transplant. - Ann. Intern. Med. 1993: 118: 173 - 178. 30. Gottstein R, Cooke RWI. Systematic review of intravenous immunoglobulin in haemolitic disease of the newborn. Arch Dis Child fetal Neonatal 2003;88:f6-f10A 31. Guglielmo BJ, Won-Beringer A, Linker CA. - Immunoglobulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Trans. 1994: 13: 499 - 510. 32. Hahn AF, Bolton CF, Zochodne D, Feasby TE,. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polineuropaty (CIDP): a double-blind, placebo-controlled, crossover study. Brain. 1996; 119: 1067-78 33. Harman K.E., Albert S. and Black M.M.: Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003;149:926-937 34. Hughes RAC, Raphael JC, Swan AV, van Doorn PA. Intravenous immunglobulin for Guillain-Barré syndrome.The Cochrane database Syst Rev 2004(1):CD002063 35. Jacobs P, Wood L, Novitzky N. Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia: a prospective randomized clinical trial. Am. J. Med 1994: 97: 55 - 59. 36. Jahnkeb L, Applebaum S, Sherman LA, Greenberger PA, Green D. An evaluation of intravenous immunoglobulin in the treatment of human immunodeficency virus-associated thrombocytopenia. Transfusion 1994; 34: 759-764 37. Jayne DR, Chapel H, Adu D et al: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity QJM 2000; 93:433-9 38. Kickler T; Braine HG; Piantadosi S; Ness PM; Herman JH; Rothko K. A randomized placebo controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 1990: 75: 313 - 316. 39. Leger JM, Chassande B, Meininger V et al.: Intravenous immunglobulin therapy in multifocal motor neuropathy: a double-blind placebo controlled study. Brain 2001;124: 145-153 40. Lee EJ; Norris D; Schiffer CA. Intravenous immune globulin for patients alloimmunized to random donor platelet tranfusion. Transfusion 1987: 27: 245 - 247. 41. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W et al. Randomized controlled trial of IVIg in untretaed chronic inflammatory demyelinating polyradiculoneuropathy Neurology 2001; 56(4):445-9 42. Mofenson LM. Bethel J. Moye J Jr. Flyer P. Nugent R. Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Journal of Acquired Immune Deficiency Syndromes. 6(10):1103-13, 1993 Oct. 43. Mofenson LM. Moye J Jr. Intravenous immune globulin for the prevention of infections in children with symptomatic human immunodeficiency virus infection. [Review] [52 refs]. Pediatric Research. 33(1 Suppl):S80-7; discussion S87-9, 1993 Jan. 44. Mollica S, Musto P, Chiurazzi F et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study . Haematologica 1996: 81: 121 -126. 45. Mueller-Eckhardt C; Kiefel V. High dose Ig for post-transfusion purpura revisited. Blut 1988; 57: 163 - 167. 46. Munoz SJ, Carabasi AR, Moritz MJ, Jarrel BE and Maddrey WC. Postoperative thrombocytopenia in liver transplant recipients: prognostic implication and treatment with hight dose of gamma-globulin. Transplantation proceedings, 1989; 21 (3): 3545-3546 47. Muti G, De Gasperi A, Nosari AM, Caimi MT,Morra E. Thrombocytopenia after liver transplantation. Response to therapy with high-dose immunoglobulin (HDIg). Brit J of Haematol, 1996; 93 (suppl. 2) 48. Newburger JW, Takahashi M, Burns JC, The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-7 49. Oates-Whitehead RM, Baumer JH, Haines L Love S et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. The Cochrane database Syst Rev 2003(4):CD004000 50. O'Donnel BF, Barr RM, Black AK, Francis DM, Kermani F, Niimi N, Barlow RJ, Winkelman RK, Greaves MW. Intravenous immunoglobulin in autoimmune chronic urticaria. British Journal of dermatology 1998 Jan; 138 (1): 101-6 51. Ohlson, A; Lacy, JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants (Review ).The Cochrane Database of Systematic Reviews – 2004 (1):CD000361 52. Ohlson, A; Lacy, JB. Intravenous immunoglobulin for suspected or subsequently proven infection in eonates. (Review ) -.The Cochrane Database Syst Rev 2004(1):CD001239 53. Otten A, Bossuyt PMM, Vermeulen M, Brand A. - Intravenous immunoglobulin treatment in hematological diseases. - Eur. J. Haematol. 1998; 60: 73 - 85. 54. Pascuzzi RM. Myastenia Gravis eand Lambert-Eaton syndrome.Ther Apher 2002 ; 61(1) :57-68 55. Pirofsky B. Intravenous immune globulin therapy in hypogammaglobulinemia. A review. Am J MEd 1984 ; 76 :53-60 56. Pyne D, Ehrenstein M and Morris V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology 2002; 41:367-374 57. Richman DP, Agius MA. Treatment principles in the management of autoimmune myastenia gravis. Ann N.Y. Acad.Sci. 2003;998:457-472 58. Robinson J, Hartling L et al.: Intravenous immunoglobulin for presumed viral myocarditis in children an adults. The Cochrane database Syst Rev 2005(1):CD004370 59. Sami N, Ali S, Bhol KC and Ahmed AR. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. JEADV 2003; 17:641-645 60. Schedel I.Application of immunoglobulin preparations in multiple myeloma. In Morel A, Nydegger UE, eds Clinical Use of Intravenous Immunoglobulins. London: Academic Press, 1986: 123- 132. 61. Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RI, Milford EL, Cho SI, Bush HIJ, Levey AS. Use of cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med 1987; 317: 1049-1054 62. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, Kirsmeier H, Larsen VA, Lee ML. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998 May.; 50 (5): 1273-1281. 63. Sullivan KM ; Kopecky KJ; Jocom J; et al. - Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. - N. Engl. J.Med 1990: 323: 705-712. 64. Tellier Z, Mouthon L. Therapeutic indications of intravenous immunglobulins. Transf Clin Biol 2003; 10:179-184 65. Van Shaik IN, Winer JB, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane database Syst Rev 2002(2):CD001797 66. Voto LS; Sexer H; Ferreiro G. et Al. Neonatal administration of high–dose intravenous immunoglobulin in rhesus haemolytic diseas. J. Perinatal Med. 1995 : 23 : 443 - 451. 67. Winston DJ , Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of CMV infection and disease in allogenic bone marrow transplant recipients: results of a placebo-controlled, duble-blind trial. An. Intern. Med. 1993: 118: 179 -184. 68. Wojnaroswka F et al: Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147(2):214-221
|
|